Evaluation of Serum Levels of Irisin and Nesfatin-1 in Patients with Migraine without Aura

Abstract

Evaluation of serum levels of irisin and nesfatin-1 in patients with migraine without aura M igraine is defined as a neurovascular disorder with neurogenic inflammation and contractile dysfunction of the cranial blood vessels [1]. It is a headache disorder that is accompanied by different combinations of neurological and autonomic disorders [2]. Clinically, there are 2 classic types of migraine: with and without aura. Migraine without aura is the most frequent form of primary headaches (60-80% of all migraines). The clinical symptoms of migraine without aura include pulsating pain, pain on at least one side of the head, sensitivity to sound and light, and vomiting and/or nausea [3]. Migraine attacks decrease quality of life (QoL), and may also cause a fiscal burden for individuals and organizations due to medical expenses. Inadequate treatment can lead to more frequent migraine attacks and more disruption for the sufferers. According to the World Health Organization (WHO), migraine is a cause of labor loss as a result of the headache pain and distress (ranking 19 th for men and 12 th for women) [4]. Many theories for the pathophysiology of migraine have been proposed. According to a neurovascular theory, migraine headaches demonstrate vascular changes in secondary neuronal activation. As a result of neuronal events, blood vessels in pain-sensitive structures expand and lead to more trigeminal nerve activation and pain [2]. The exact pathology of migraine has yet to be fully understood. In 1 novel study, it was proposed that cytokines and some neuropeptides may have an important role in the pathogenesis of migraine [5]. Recent research has focused on the association between mi-Objectives: Migraine is a chronic neurological disorder. A number of cytokines have been linked to the pathogenesis of migraine. This is a preliminary assessment to determine and analyze the serum levels of irisin and nesfatin-1 in patients with migraine without aura. Methods: A total of 80 participants, 40 patients who had been diagnosed with migraine without aura (10 men, 30 women) and 40 healthy controls (10 men, 30 women), were included in the study. The serum irisin and nesfatin-1 parameters were investigated using blood samples drawn from the patient and control groups. Results: The mean serum irisin level was 16.87±14.66 ng/mL in the migraine group and 17.33±17.18 ng/mL in the healthy controls. No significant p value was determined (p=0.470), but the level was slightly lower in the migraine group. The mean nesfatin-1 level was 4.71±5.96 mmol/L in the migraine group and 4.13±5.41 mmol/L in the healthy controls (p=0.19), again revealing a small but statistically insignificant difference. In addition, there was no statistically significant difference according to age group, visual analog scale score for pain, body mass index, or length of disease duration. Conclusion: Although no statistically significant differences were observed, the present study is believed to be the first to provide insight on the serum levels of irisin and nesfatin...